Regeneron shares fell 5.24% to $693.43 after reporting a 10% drop in Q1 Eylea sales to $941 million.
Eylea HD sales weakened due to lower wholesaler inventory and regulatory delays on its pre‑filled syringe version.
Adjusted Q1 earnings were $9.47 per share, beating $8.94 estimates, while a lung‑cancer combo was halted before late‑stage trials.